Karuna Therapeutics Inc's Comment on Sales, Marketing and Customers
The Company applies the ASC 606 revenue recognition standard to contracts with customers, excluding those governed by other standards such as leases, insurance, collaboration arrangements, and financial instruments. Revenue is recognized through a five-step process when customers obtain control of promised goods or services. The Company assesses contracts to identify performance obligations, including options that provide material rights, and recognizes revenue accordingly. It evaluates whether promised goods or services are distinct based on the customer's ability to benefit from them independently and whether the promises are separately identifiable within the contract. In collaboration or licensing arrangements, the Company considers factors such as the research, manufacturing, and commercialization capabilities of collaboration partners, the availability of expertise in the marketplace, and the intended benefit of the contract in determining distinct performance obligations.
Karuna Therapeutics, a leading biopharmaceutical company focused on developing innovative treatments for psychiatric and neurological disorders, has recently released its financial results for the fourth quarter and full year ended December 31, 2023. With groundbreaking achievements, including FDA acceptance of its New Drug Application (NDA) for KarXT in schizophrenia treatment, Karuna Therapeutics has proven its commitment to transforming the lives of patients living with mental health conditions. This article aims to provide an in-depth analysis of Karuna Therapeutics financial performance, business updates, and the potential impact of its advancements in the field of pharmaceutical sciences.Financial Res...
Karuna Therapeutics Inc’s Comment on Sales, Marketing and Customers
The Company applies the ASC 606 revenue recognition standard to contracts with customers, excluding those governed by other standards such as leases, insurance, collaboration arrangements, and financial instruments. Revenue is recognized through a five-step process when customers obtain control of promised goods or services. The Company assesses contracts to identify performance obligations, including options that provide material rights, and recognizes revenue accordingly. It evaluates whether promised goods or services are distinct based on the customer's ability to benefit from them independently and whether the promises are separately identifiable within the contract. In collaboration or licensing arrangements, the Company considers factors such as the research, manufacturing, and commercialization capabilities of collaboration partners, the availability of expertise in the marketplace, and the intended benefit of the contract in determining distinct performance obligations.
Sources:
Karuna Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Karuna Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Karuna Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
